ipilimumab
bms
['melanoma', 'yervoy', 'ipilimumab']
for patients with advanced #melanoma, tumor-infiltrating lymphocyte (til) therapy more than doubled pfs compared with the anti-ctla-4 drug ipilimumab (yervoy), according to results presented at #esmo22. 
OBR is an oncology-focused digital media company that provides news and information resources to oncology professionals.